Kershaw Patel
Internal Medicine · Chicago, ILNPI 1215375019
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $14,149 of the $14,701 with a category attached, or 96.2%. Novo Nordisk accounts for 64.2% of it on its own, with 6 other manufacturers making up the rest. 2025 is the largest year on record at $5,163, more than ten times the $122 reported in 2021. Among internal medicine clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 26 payments — averaging $565.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$9K
- Roche Diagnostics Corporation$5K
- Amgen$135
- Corcept Therapeutics$50
- Pfizer$38
- Impulse Dynamics (USA) Inc.$26
- plus $15 from 1 others
What the payments were for
- Consulting fees$14,14996%
- Food & beverage$4553%
- Education$971%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 12 | $9,438 |
| Roche Diagnostics Corporation | 1 | $4,999 |
| Amgen | 8 | $135 |
| Corcept Therapeutics | 1 | $50 |
| Pfizer | 2 | $38 |
| Impulse Dynamics (USA) Inc. | 1 | $26 |
| Boehringer Ingelheim | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$4,650
How this compares
$14,701 in reported general payments places this provider in the 95th percentile of 5,182 internal medicine providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 73 | $87,298 |
| XareltoRivaroxaban | 71 | $80,552 |
| FarxigaDapagliflozin Propanediol | 61 | $65,699 |
| JardianceEmpagliflozin | 31 | $36,832 |
| OzempicSemaglutide | 33 | $33,330 |
| Repatha SureclickEvolocumab | 41 | $22,154 |
| Repatha SyringeEvolocumab | 13 | $7,342 |
| Rosuvastatin Calcium | 273 | $3,910 |
| Ezetimibe | 110 | $3,092 |
| Atorvastatin Calcium | 247 | $1,891 |
| Spironolactone | 122 | $1,351 |
| Metoprolol Succinate | 112 | $1,271 |
| Amlodipine Besylate | 188 | $1,200 |
| Losartan Potassium | 83 | $987 |
| Lisinopril | 112 | $703 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $38 | $87,29873 claims |
| Boehringer IngelheimJardiance | $15 | $36,83231 claims |
| Novo NordiskOzempic | $9,438 | $33,33033 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,182 internal medicine providers in Illinois.
Other internal medicine in Chicago
- Merle DiamondChicago$1.1M
- Robert KushnerChicago$516K
- Romeo UrsuaChicago$420K
- Peter O DonnellChicago$318K
- George UrbanChicago$258K
- Kristen PallokChicago$256K
- George NissanChicago$252K
- Luke LaffinChicago$162K
- Daniel CatenacciChicago$161K
- Hiren ShahChicago$144K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.